New Drug for Schizophrenia Targets Muscarinic Receptors

January 2025

You’ll hear talk about xanomeline/trospium (Cobenfy), the first in a new class of drugs approved to treat schizophrenia in decades.

Until now, we have mostly treated schizophrenia with antipsychotics that primarily block dopamine and serotonin receptors.

Xanomeline/trospium is different. It’s an oral agonist/antagonist combo that works on muscarinic receptors in the CNS.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote